NAPROSYN (naproxen) by Hamilton medical is cyclooxygenase inhibitors [moa]. First approved in 1987.
Drug data last refreshed 14h ago · AI intelligence enriched 3d ago
NAPROSYN (naproxen) is an oral nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes to reduce pain, inflammation, and fever. It is available as a suspension formulation and is indicated for various inflammatory and pain conditions. The drug has been on the market since 1987 and remains a widely used over-the-counter and prescription NSAID.
As a mature NSAID facing loss of exclusivity, the product likely operates with a stable but lean team focused on cost management and generic transition strategies rather than growth initiatives.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers
A Multiple-Dose Safety Study of Fixed Combination of Acetaminophen/Naproxen Sodium in Adolescents With Orthodontic Pain
A Study of Acetaminophen/Naproxen Sodium Fixed Combination Tablets in Adolescents 12 to <17 Years of Age With Pain
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy
A Study of an Acetaminophen/Naproxen Sodium Fixed Combination, Acetaminophen and Naproxen Sodium in Postoperative Dental Pain
Worked on NAPROSYN at Hamilton medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on NAPROSYN offers career experience in mature product management, generic transition strategy, and cost-containment negotiations rather than growth-stage innovation. Professionals on this team develop expertise in managed care, payer relations, and defending market share against generics, which are valuable skills in late-lifecycle portfolio management.